Literature DB >> 25438812

Benefits of dynamic susceptibility-weighted contrast-enhanced perfusion MRI for glioma diagnosis and therapy.

Ramon Francisco Barajas1, Soonmee Cha.   

Abstract

Glioma are the most common supra-tentorial brain tumor in the USA with an estimated annual incidence of 17,000 new cases per year. Dynamic susceptibility-weighted contrast-enhanced (DSC) perfusion MRI noninvasively characterizes tumor biology allowing for the diagnosis and therapeutic monitoring of glioma. This MRI technique utilizes the rapid changes in signal intensity caused by a rapid intravascular bolus of paramagnetic contrast agent to calculate physiologic perfusion metrics. DSC perfusion MRI has increasingly become an integrated part of glioma imaging. The specific aim of this article is to review the benefits of DSC perfusion MRI in the therapy of glioma.

Entities:  

Keywords:  cerebral blood volume; dynamic susceptibility-weighted contrast-enhanced perfusion MRI; glioblastoma; glioma; imaging genomics; metastasis; molecular imaging; peak height; percentage of signal intensity recovery

Mesh：

Year:  2014        PMID： 25438812      PMCID： PMC4277861          DOI： 10.2217/cns.14.44

Source DB:  PubMed          Journal:  CNS Oncol        ISSN： 2045-0907


  59 in total

1.  Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas.

Authors:  Meng Law; Sarah Oh; Glyn Johnson; James S Babb; David Zagzag; John Golfinos; Patrick J Kelly
Journal:  Neurosurgery       Date:  2006-06       Impact factor: 4.654

2.  Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements.

Authors:  L S Hu; L C Baxter; K A Smith; B G Feuerstein; J P Karis; J M Eschbacher; S W Coons; P Nakaji; R F Yeh; J Debbins; J E Heiserman
Journal:  AJNR Am J Neuroradiol       Date:  2008-12-04       Impact factor: 3.825

3.  Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging.

Authors:  Ramon F Barajas; Joanna J Phillips; Rupa Parvataneni; Annette Molinaro; Emma Essock-Burns; Gabriela Bourne; Andrew T Parsa; Manish K Aghi; Michael W McDermott; Mitchel S Berger; Soonmee Cha; Susan M Chang; Sarah J Nelson
Journal:  Neuro Oncol       Date:  2012-06-18       Impact factor: 12.300

4.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

5.  Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging.

Authors:  Robert G Whitmore; Jaroslaw Krejza; Gurpreet S Kapoor; Jason Huse; John H Woo; Stephanie Bloom; Joanna Lopinto; Ronald L Wolf; Kevin Judy; Myrna R Rosenfeld; Jaclyn A Biegel; Elias R Melhem; Donald M O'Rourke
Journal:  J Neurosurg       Date:  2007-09       Impact factor: 5.115

6.  Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.

Authors:  S Cha; J M Lupo; M-H Chen; K R Lamborn; M W McDermott; M S Berger; S J Nelson; W P Dillon
Journal:  AJNR Am J Neuroradiol       Date:  2007 Jun-Jul       Impact factor: 3.825

7.  Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.

Authors:  Christopher E Pelloski; Karla V Ballman; Alfred F Furth; Li Zhang; E Lin; Erik P Sulman; Krishna Bhat; J Matthew McDonald; W K Alfred Yung; Howard Colman; Shiao Y Woo; Amy B Heimberger; Dima Suki; Michael D Prados; Susan M Chang; Fred G Barker; Jan C Buckner; C David James; Kenneth Aldape
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

8.  High cerebral blood volume in human gliomas predicts deletion of chromosome 1p: Preliminary results of molecular studies in gliomas with elevated perfusion.

Authors:  Meng Law; Jennie E Brodsky; James Babb; Marc Rosenblum; Douglas C Miller; David Zagzag; Michael L Gruber; Glyn Johnson
Journal:  J Magn Reson Imaging       Date:  2007-06       Impact factor: 4.813

9.  Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours.

Authors:  Michael D Jenkinson; Trevor S Smith; Kathy A Joyce; Diane Fildes; John Broome; Daniel G du Plessis; Brian Haylock; David J Husband; Peter C Warnke; Carol Walker
Journal:  Neuroradiology       Date:  2006-08-26       Impact factor: 2.804

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088
View more
  11 in total

1.  Effect of color visualization and display hardware on the visual assessment of pseudocolor medical images.

Authors:  Silvina Zabala-Travers; Mina Choi; Wei-Chung Cheng; Aldo Badano
Journal:  Med Phys       Date:  2015-06       Impact factor: 4.071

2.  Standardized acquisition and post-processing of dynamic susceptibility contrast perfusion in patients with brain tumors, cerebrovascular disease and dementia: comparability of post-processing software.

Authors:  Manuel Alexander Schmidt; Michael Knott; Philip Hoelter; Tobias Engelhorn; Elna Marie Larsson; Than Nguyen; Marco Essig; Arnd Doerfler
Journal:  Br J Radiol       Date:  2019-10-24       Impact factor: 3.039

3.  Magnetic resonance perfusion image features uncover an angiogenic subgroup of glioblastoma patients with poor survival and better response to antiangiogenic treatment.

Authors:  Tiffany T Liu; Achal S Achrol; Lex A Mitchell; Scott A Rodriguez; Abdullah Feroze; Michael Iv; Christine Kim; Navjot Chaudhary; Olivier Gevaert; Josh M Stuart; Griffith R Harsh; Steven D Chang; Daniel L Rubin
Journal:  Neuro Oncol       Date:  2017-07-01       Impact factor: 12.300

4.  Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.

Authors:  Caixing Sun; Yang Yu; Lizhen Wang; Bin Wu; Liang Xia; Fang Feng; Zhiqiang Ling; Shihua Wang
Journal:  J Exp Clin Cancer Res       Date:  2016-02-13

5.  Comparison among conventional and advanced MRI, 18F-FDG PET/CT, phenotype and genotype in glioblastoma.

Authors:  Maria Consuelo Valentini; Marta Mellai; Laura Annovazzi; Antonio Melcarne; Tetyana Denysenko; Paola Cassoni; Cristina Casalone; Cristiana Maurella; Silvia Grifoni; Piercarlo Fania; Angelina Cistaro; Davide Schiffer
Journal:  Oncotarget       Date:  2017-10-04

Review 6.  Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges.

Authors:  Junfeng Zhang; Heng Liu; Haipeng Tong; Sumei Wang; Yizeng Yang; Gang Liu; Weiguo Zhang
Journal:  Contrast Media Mol Imaging       Date:  2017-03-20       Impact factor: 3.161

7.  The Value of APTw CEST MRI in Routine Clinical Assessment of Human Brain Tumor Patients at 3T.

Authors:  Julia P Lingl; Arthur Wunderlich; Steffen Goerke; Daniel Paech; Mark E Ladd; Patrick Liebig; Andrej Pala; Soung Yung Kim; Michael Braun; Bernd L Schmitz; Meinrad Beer; Johannes Rosskopf
Journal:  Diagnostics (Basel)       Date:  2022-02-14

8.  Sequential implementation of DSC-MR perfusion and dynamic [18F]FET PET allows efficient differentiation of glioma progression from treatment-related changes.

Authors:  Eike Steidl; Karl-Josef Langen; Sarah Abu Hmeidan; Nenad Polomac; Christian P Filss; Norbert Galldiks; Philipp Lohmann; Fee Keil; Katharina Filipski; Felix M Mottaghy; Nadim Jon Shah; Joachim P Steinbach; Elke Hattingen; Gabriele D Maurer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-11-26       Impact factor: 9.236

Review 9.  MRI and PET of Brain Tumor Neuroinflammation in the Era of Immunotherapy, From the AJR Special Series on Inflammation.

Authors:  Cymon N Kersch; Prakash Ambady; Bronwyn E Hamilton; Ramon F Barajas
Journal:  AJR Am J Roentgenol       Date:  2021-07-14       Impact factor: 6.582

10.  AG488 as a therapy against gliomas.

Authors:  Jadith Ziegler; Anja Bastian; Megan Lerner; Lora Bailey-Downs; Debra Saunders; Nataliya Smith; Jake Sutton; James D Battiste; Michael A Ihnat; Aleem Gangjee; Rheal A Towner
Journal:  Oncotarget       Date:  2017-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.